AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04559282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Sound Processor
Description: The new Sound Processor is intended to be used as part of the Cochlear Baha System which uses bone conduction to transmit sounds to the cochlea. The New Sound Processor is indicated for patients with up to 55 dB sensorineural hearing loss.
Study NCT04508296 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Goal directed de-escalation therapy
Description: Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT in the case of GEDVI > 650 mL/m2 or EVLWI > 10 mL/kg depending on the randomization group. The primary goal of de-escalation was to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI \< 650 mL/m2 or EVLWI \< 10 mL/kg, the target fluid balance was in the range of 0 to +3000 mL
Study NCT00965796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 2 mg/kg/h- during surgical procedure Saline
Study NCT03492736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 30 days 10mg Melatonin taken nightly 1 hour before bed
Study NCT03492736 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 days placebo taken nightly 1 hour before bed
Study NCT02980003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline
Description: patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure.
Study NCT02980003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: i.v. sodium bicarbonate
Description: patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The patient receives solution of 1.4% sodium bicarbonate (167 mEq/L; 334 mOsm/L) one hours and six hours after procedure.
Study NCT02980003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral sodium bicarbonate
Description: patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water
Study NCT02749851 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.
Study NCT02749851 — intervention group
Intervention type: DEVICE
Intervention: MRI - IUGR
Description: Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy. The objective of this ancillary arm is to further test the sensitivity of placental magnetic resonance imaging to detect abnormal perfusion and oxygenation in confirmed cases of IUGR between gestational ages 28 to 36 weeks.
Study NCT02784223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation : PET-CT with F18-choline examination
Description: PET-CT with F18-choline examination will be performed before surgery
Study NCT03395249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR994
Description: SAD: Double-blind dosing will occur in all SAD Cohorts except for Cohort 12. In each cohort, six subjects will receive one of five different timed release formulations of SPR994 and 2 subjects will receive placebo. Subjects in SAD Cohorts 2, 3, 6, 16 and 17 will receive a single dose following a 10-h fast. Subjects in SAD Cohorts 1, 8-15 will receive one dose of SPR994 or placebo following a 10-h fast on Day 1 and a second dose following consumption of a standardized meal on Day 7. The dose escalation steps may be altered following review of the safety data of each cohort.~MAD: Double-blind dosing will occur in all MAD Cohorts. Subjects will receive multiple doses of an optimal timed release formulation of SPR994 in MAD Cohort 4 (300 mg) and Cohort 5 (600 mg) or placebo for 14 consecutive days at either BID or TID dosing beginning on Day 1.
Study NCT03395249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Mannitol 200SD SAD: Two subjects in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
Study NCT03395249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Orapenem®
Description: Tebipenem pivoxil granules
Study NCT04394845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: \[18F\]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]), with a maximum drug mass dose of 10 microgram (μg).
Study NCT01779479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabacitaxel
Description: Cabazitaxel 25 mg/m² i.v. (Day 1) every 3 weeks (cycle) as 1-hour i.v infusion for a total of up to 4 cycles over a maximum total treatment period of 15 weeks before surgery
Study NCT01779479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m² as 1-hour i.v infusion. Patients will receive weekly (Days 1, 8, 15) paclitaxel administrations for a maximum of 12 infusions for a maximum of 4 cycles over a maximum total treatment period of 15 weeks before surgery (1 cycle = 3 weeks).
Study NCT01381874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
Study NCT01381874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane
Description: Prednisone or Prednisolone, type=equal, unit=mg, number=5, form=tablet, route=oral use. All drugs are taken once daily.
Study NCT01381874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate + Prednisone or Prednisolone
Description: Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
Study NCT04530539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1000mg Vitamin C, at bedtime
Study NCT04530539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: 10mg melatonin, at bedtime
Study NCT04530539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at bedtime
Study NCT04530539 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Symptom Survey
Description: Daily symptom survey to be completed by patient electronically
Study NCT04530539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Survey
Description: Daily symptom survey to be completed by patient electronically
Study NCT01110343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness intervention
Description: a 6 -week behavioral intervention lasting 1.5 hours per week with a trained parent mentor, 3 monthly booster sessions and follow-up
Study NCT01110343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional parent Support Group
Description: a 6 week behavioral program, consisting of 1.5 hour weekly sessions run by a trained parent mentor with a structured curriculum based on the strengths of support groups like emotional support, advocacy and training. There are 3 monthly booster sessions and follow-up.
Study NCT04114747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starting at high or low blood pressure
Description: Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target
Study NCT04232046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Massage the trigger points in 8 different points for 1 min in circle direction and 3 times a day.
Study NCT04232046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage the trigger points in 8 different points for 1 min in circle direction and 3 times a day.
Study NCT00452413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: Administered orally
Study NCT04053140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin G_1200mg
Description: Benzylpenicillin IV 1200mg administered every 4 hours.
Study NCT04053140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin G_2400mg
Description: Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.
Study NCT04053140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin G_600mg/hr
Description: Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
Study NCT03349554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: body-scan meditation
Description: 15 minutes audio-guided body-scan meditation
Study NCT03349554 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Psychological evaluation
Description: NPI (Neuropsychiatric symptoms Inventory) - PAS (Parkinson's disease Anxiety Screening Questionnaire) - VAS measuring pain, anxiety and discomfort Before and after body-scan meditation
Study NCT03945370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: β-hydroxybuturate esters
Description: Oral dietary supplement product containing β-hydroxybuturate esters
Study NCT03945370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: β-hydroxybuturate esters
Description: Oral dietary supplement product containing β-hydroxybuturate esters
Study NCT03945370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo drink
Description: Oral placebo drink
Study NCT03945370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Oral placebo drink
Study NCT03425409 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Integra Pulse Portable- Continuous flow
Description: 4 liters per minute oxygen flow
Study NCT03425409 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Integra Pulse Portable- Pneumatic pulsed flow
Description: Oxygen flow determined by test device
Study NCT02729038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.
Study NCT04603768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraband exercises
Description: Group A performed theraband exercises for 6 weeks.In the first 2 weeks theraband with low resistance was used to perform exercises and then we proceeded gradually with higher resistance therabands.Theraband exercises was performed for Shoulder Flexion,Shoulder Extension Strengthening, Shoulder Internal Rotation Strengthening, Shoulder External Rotation Strengthening, Shoulder Abduction, Empty Can Exercise \& Rowing Exercise with 8-10 reps, 3sec hold and 2-3 sets With each of these exercises
Study NCT04603768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-contraction exercises
Description: Muscle co-contraction is the simultaneous contraction of the muscles acting around a joint. Subject stood upright \& contracted both the groups (agonist and antagonist) simultaneously without bringing movement at shoulder joint with 6-8 reps , 3sets \& 5- 15 seconds duration of sustained self-arm bracing or stiffening was maintained.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week
Study NCT00452413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Administered orally
Study NCT03084497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infant Massage
Description: The first day, investigators will make the initial assessment of the baby through Psychomotor Development Scale of Early Childhood Brunet- Lézine. Participants will keep the sessions early attention and will participate in the course of Infant Massage, which develop for 5 weeks.~Infant Massage course will take place with families and is based on the methodology and program of the International Association of Infant Massage ( IAIM ), created by Vimala McClure. The course will consist of 5 sessions (one per week) approximately 90 minutes. Parents will practice everyday the movements learned during the time of the study.~When the course of Infant Massage finished, Investigators will conduct the final evaluation of the baby, the same way as in the initial evaluation.
Study NCT02761889 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT 45 Gy in 5 fractions of 9 Gy
Description: Previously untreated patients with prostate cancer will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
Study NCT02761889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)
Description: Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
Study NCT02761889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal balloon with air filling
Description: A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
Study NCT02761889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urethral catheter loaded with beacon transponders
Description: A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
Study NCT01529671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension twice daily (BID)
Study NCT01529671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension BID
Study NCT00318149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: 1 dose administered intramuscularly in the deltoid region of the non-dominant arm
Study NCT00318149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix-AS25
Description: 1 dose administered intramuscularly into the deltoid region of the non-dominant arm
Study NCT00318149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix-AS50
Description: 1 dose administered intramuscularly into the deltoid region of the non-dominant arm
Study NCT00318149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix-AS01B
Description: 1 dose administered intramuscularly into the deltoid region of the non-dominant arm
Study NCT00318149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix-AS01E
Description: 1 dose administered intramuscularly into the deltoid region of the non-dominant arm
Study NCT04603768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercises
Description: Isometric exercises of shoulder were performed in subjects for 6 weeks which included isometric Shoulder flexion, shoulder abduction isometric exercise, isometric shoulder external rotation, isometric shoulder internal rotation \& isometric shoulder extension with 8-10 reps, 5 sec hold and 2 sets.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week
Study NCT02798289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Intranasal Neurostimulator
Description: Neurostimulation device
Study NCT04031521 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Near infrared spectroscopy
Description: NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.
Study NCT03047772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Routine dose of Atorvastatin therapy
Study NCT03047772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Routine dose of Atorvastatin therapy
Study NCT03047772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Routine dose of Atorvastatin therapy
Study NCT03047772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intensive Atorvastatin
Description: Intensive dose of Atorvastatin therapy
Study NCT03047772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive Atorvastatin
Description: Intensive dose of Atorvastatin therapy
Study NCT03047772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose BMMSC
Description: Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Study NCT03047772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle dose BMMSC
Description: Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Study NCT03047772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose BMMSC
Description: High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Study NCT03047772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation
Description: Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Study NCT03047772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplantation
Description: Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Study NCT02667886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: Continuous, oral dosing
Study NCT02667886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Continuous, oral dosing
Study NCT03461848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYPHP Evelina London Model of care
Description: Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Targeted services offered dependent on need. Children with any of the tracer conditions will be offered pathway based care including early intervention for physical and related mental health needs, paediatric nursing support, care plans shared with schools, medication reviews, and peer-led parenting support. Self-management support, social support signposting, and safety-netting are offered to all.
Study NCT03461848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Self-management support, social support signposting, and safety-netting are offered to all.
Study NCT04485715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI system
Description: The real-time assistance of AI system
Study NCT01621204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) 21 days before surgery. Dose may be adjusted based on subsequent platelet counts (minimum 25mg; maximum 75mg).
Study NCT01621204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG infusion
Description: IVIG infusion (1-2 g/kg) given 7 (+/-2) days prior to surgery; with an additional infusion allowed within one week of achievement of surgical hemostasis, if needed
Study NCT02778399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for oral administration once daily
Study NCT02778399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE2109
Description: OBE2109 tablets for oral administration once daily
Study NCT02778399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OBE2109
Description: OBE2109 tablets for oral administration once daily
Study NCT02011425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mandibular advancement appliance
Description: mandibular advancement appliance
Study NCT04011332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Care Model
Description: The patients who are hospitalised due to a COPD exacerbation will be aligned to a nurse-led integrated care model for three months. The model constitutes a bundle of interventions that are commonly known as key elements in COPD management. In addition, the ANP-Team (Advanced Nursing Practice-Team) will coordinate the different health professionals within the hospital and across transitions within the three months.